Bristol-Myers Squibb Company (BMY)
Largest Insider Buys in Sector
BMY Stock Price History Chart
BMY Stock Performance
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients …
Insider Activity of Bristol-Myers Squibb Company
Over the last 12 months, insiders at Bristol-Myers Squibb Company have bought $349,664 and sold $38,931 worth of Bristol-Myers Squibb Company stock.
On average, over the past 5 years, insiders at Bristol-Myers Squibb Company have bought $3.93M and sold $35.35M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BOERNER CHRISTOPHER S. (Chief Executive Officer) — $249,609. Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) — $100,055.
The last purchase of 1,830 shares for transaction amount of $100,055 was made by Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) on 2024‑11‑01.
List of Insider Buy and Sell Transactions, Bristol-Myers Squibb Company
| 2024-11-04 | Sale | SVP and Controller | 700 <0.0001% | $55.62 | $38,931 | +4.38% | ||
| 2024-11-01 | EVP,Chief Med.Offr.,Drug Dev. | 1,830 <0.0001% | $54.67 | $100,055 | +5.03% | |||
| 2023-12-05 | Chief Executive Officer | 2,000 <0.0001% | $49.78 | $99,560 | -0.84% | |||
| 2023-11-28 | Chief Executive Officer | 3,071 0.0002% | $48.86 | $150,049 | +1.92% | |||
| 2023-11-20 | director | 8,500 0.0004% | $49.81 | $423,385 | +1.68% | |||
| 2023-08-24 | Sale | EVP, Chief Human Resources | 17,986 0.0009% | $61.25 | $1.1M | -17.67% | ||
| 2023-08-03 | Sale | EVP, Chief Research Officer | 732 <0.0001% | $61.14 | $44,754 | -16.89% | ||
| 2023-05-03 | Sale | EVP & President, Research | 50,385 0.0024% | $67.06 | $3.38M | -19.35% | ||
| 2023-02-06 | Sale | Board Chair and CEO | 240,000 0.0115% | $74.65 | $17.92M | -15.58% | ||
| 2023-02-06 | Sale | EVP, Chief Human Resources | 11,183 0.0005% | $74.69 | $835,258 | -15.58% | ||
| 2022-11-09 | Sale | EVP, Chief Human Resources | 16,250 0.0008% | $80.45 | $1.31M | -15.55% | ||
| 2022-11-07 | Sale | EVP, Research & Early Dev. | 45,910 0.0022% | $78.88 | $3.62M | -14.63% | ||
| 2022-09-20 | Sale | Board Chair and CEO | 25,000 0.0012% | $69.71 | $1.74M | +0.62% | ||
| 2022-09-15 | Sale | Board Chair and CEO | 50,000 0.0023% | $71.84 | $3.59M | -2.19% | ||
| 2022-09-14 | Sale | EVP, Chief Human Resources | 25,000 0.0012% | $70.75 | $1.77M | -0.31% | ||
| 2022-09-13 | Sale | EVP, Chief Financial Officer | 133,951 0.0063% | $71.30 | $9.55M | -1.02% | ||
| 2022-06-13 | Sale | Board Chair and CEO | 30,000 0.0014% | $74.04 | $2.22M | -0.89% | ||
| 2022-06-06 | Sale | EVP, General Counsel | 65,000 0.003% | $74.89 | $4.87M | -2.93% | ||
| 2022-03-21 | Sale | Board Chair and CEO | 25,000 0.0012% | $71.52 | $1.79M | +5.53% | ||
| 2022-03-16 | Sale | EVP, Research & Early Dev. | 31,331 0.0015% | $69.27 | $2.17M | +7.64% |
Insider Historical Profitability
| BOERNER CHRISTOPHER S. | Chief Executive Officer | 82672 0.0041% | $58.70 | 2 | 1 | |
| Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 62109 0.0031% | $58.70 | 1 | 0 | |
| CELGENE CORP /DE/ | 10 percent owner | 7008510 0.3456% | $58.70 | 1 | 1 | +6.23% |
| SIGAL ELLIOT | EVP, CSO & President R&D | 148221 0.0073% | $58.70 | 1 | 10 | +21.52% |
| CORNELIUS JAMES M | director | 119464 0.0059% | $58.70 | 2 | 116 | +5.54% |
Institutional Investor Ownership
| The Vanguard Group | $10.09B | 9.18 | 186.07M | -6.1% | -$655.79M | 0.19 | |
| BlackRock | $8.82B | 8.02 | 162.56M | -3.3% | -$300.58M | 0.19 | |
| State Street | $4.97B | 4.52 | 91.57M | +2.38% | +$115.23M | 0.2 | |
| JPMorgan Chase | $4.82B | 4.38 | 88.81M | -1.37% | -$66.93M | 0.43 | |
| Capital International Investors | $3.81B | 3.46 | 70.2M | +14.1% | +$470.46M | 0.77 |